Hard to Treat Diseases Inc.
HTDS
Other OTC0.00
USD
- -
- -
ISIN
US41164A1034
CUSIP
41164A103
Return %
Stock
S&P500
1Y
0.00
19.01
3Y
100.00
65.48
5Y
100.00
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Shimin Yuan
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2655 Ulmerton Road Clearwater FL United States of America 33762
- IPO Date
- Sep 25, 1998
- Website
- htdsmedical.com
- Similar Companies
- Business
- Hard to Treat Diseases Inc. (HTDS) manufactures, supplies, exports, and markets biopharmaceuticals, biological vaccines, and related medical products primarily in China and internationally; its core offerings include research, development, purchase, and sale of biologics through subsidiaries such as Slavica Bio Chem Co. and China Mellow Hope Inc., with exclusive agency rights for international marketing and sales of products from partners like Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd., encompassing H1N1 vaccines and other hard-to-treat disease therapeutics. The company, founded in 2009 and headquartered at Room EF, 12F, Jinrun Mansion in Shenzhen, Guangdong Province, China, operates in the healthcare distributors industry within the broader healthcare sector, targeting pharmaceutical and vaccine markets across Europe, Mainland China, and global regions. Recent activities include closing a previously announced $18 million deal to expand its biopharmaceutical business, alongside historical strategic moves such as pursuing mergers with biotechnology firms focused on blood transfusion products and planning share buyback programs, though financial reporting remains limited with last earnings data from 2010.